AstraZeneca sells cancer drug to Sanofi for $300m
27th Jul 2015 08:45
(ShareCast News) - AstraZeneca has entered into a definitive agreement with Sanofi's rare diseases unit, Genzyme, to divest Caprelsa, which is used to treat a rare type of cancer. Under the terms of the deal, Genzyme will pay up to $300m to AstraZeneca, including an upfront payment of $165m to acqui
Read moreAstraZeneca divests international gastroenterolgy drug rights to Tillotts Pharma
17th Jul 2015 08:41
(ShareCast News) - Pharmaceuticals giant AstraZeneca has completed its agreement with Tillotts Pharma, part of the Zeria Group, for the divestment of global rights outside the US, to Entocort, which is a gastroenterology medicine for patients with mild to moderate Crohn's disease and ulcerative coli
Read moreFTSE 100 movers: Meggitt surges on merger mumbles, Carney chat hits housebuilders
14th Jul 2015 14:29
(ShareCast News) - London markets edged lower on Tuesday, as losses from housebuilders, engineers and financials eclipsed gains made by industrial metals. As of 14:00 BST, the FTSE 100 was trading 0.2% lower at 6,727. Shares in defence and aerospace engineer Meggitt rose following a report in the F
Read moreLondon midday: Homebuilders knocked lower by remarks from Carney
14th Jul 2015 13:09
(ShareCast News) - Bank of England Governor Mark Carney told the Treasury Select Committee Bank Rate may be headed higher a little bit sooner than markets anticipated, sending stocks - especially homebuilders - listed on the second tier index promptly lower. As of 12:13 the top flight index was off
Read moreMonday broker round-up
13th Jul 2015 12:05
(ShareCast News) - ARM Holdings: JP Morgan downgrades to underweight and lowers target to 900p from 950p; Exane reiterates outperform with 1,400p target. AstraZeneca: Goldman Sachs stays at neutral and Jefferies at buy. British American Tobacco: Nomura starts coverage at buy with 3,920p target. Bu
Read moreAstrazeneca offloads Crohn's treatment for $215m
9th Jul 2015 09:01
Astrazeneca has sold global rights outside the US for its Entocort medicine, which treats Crohn's disease and ulcerative colitis, to Japan's Zeria Group for $215m Entocort generated product sales of $53m outside the US in 2014 for the FTSE 100 drug group, which said the disposal to Zeria subsidiary
Read moreFTSE 100 movers: Defensives gain, miners sold off as risk appetite wanes
7th Jul 2015 15:16
Defensive sectors such as real estate and pharmaceuticals were performing well while commodity stocks were falling on Tuesday, with investors reducing their appetite for risk as European leaders met in Brussels to discuss Greece's future. Stocks which tend to hold up better in times of economic inst
Read moreSunday share tips: Astrazeneca, Galliford Try, Grainger
5th Jul 2015 13:56
Buy shares in Astrazeneca said Questor in the Sunday Telegraph. The London-listed company is one of the foremost developers of cancer treatments in the world, especially in the exciting new field of immuno-oncology, which use the body's own immune system to recognise and destroy cancer cells. Analys
Read moreSunday share tips: Astrazeneca, Galliford Try, Grainger
5th Jul 2015 13:56
Buy shares in Astrazeneca said Questor in the Sunday Telegraph. The London-listed company is one of the foremost developers of cancer treatments in the world, especially in the exciting new field of immuno-oncology, which use the body's own immune system to recognise and destroy cancer cells. Analys
Read moreBroker tips: Serco, Smiths Group, Jimmy Choo, AstraZeneca
2nd Jul 2015 11:22
Serco's stock was extending gains on Wednesday after a well-received first-half trading update the day before, with Numis Securities providing a further boost by upgrading its recommendation from 'reduce' to 'hold'. Numis said Serco revelations that first-half trading had been a little better than e
Read moreBerenberg ups AstraZeneca to 'buy'; says oncology pipeline will drive growth
2nd Jul 2015 09:02
Berenberg upgraded AstraZeneca to 'buy' from 'hold' and raised the price target to 5,200p from 4,800p, saying that Oncology will drive future growth. Berenberg noted that AZN shares reached highs of 4,800p during last year's Pfizer approach. Since then, sentiment has weakened and the shares are not
Read moreFriday broker round-up
26th Jun 2015 10:11
ARM Holdings: Bernstein downgrades to underperform. GlaxoSmithKline: Liberum ups view to hold from sell. HSBC initiates coverage at buy with 1,700p target. AztraZeneca: HSBC initiates coverage at hold with 4,640p target. Qinetiq: UBS downgrades to sell from neutral. Meggitt: UBS raises view to ne
Read moreHSBC initiates coverage of European pharmaceuticals Astra, GSK, Hikma and Shire
26th Jun 2015 07:51
HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue. Although some pharma companies, such as AstraZeneca, still face generic pressure for drugs that contribute significantly to their top and bottom lines, the majority are largel
Read moreBoris Johnson to suggest creating a "megafund" for biotech firms
25th Jun 2015 11:53
London mayor Boris Johnson on Thursday suggested that banks, investors and drug multinationals should condier creating a £10bn "megafund" to help biotech firms in the country to compete with US rivals. Johnson made the suggestion on the occasion of a conference in London that brought together the le
Read moreTuesday broker round-up
23rd Jun 2015 08:03
Acacia Mining: Morgan Stanley keeps at equalweight, raises target to 285p from 251p. BHP Billiton: Morgan Stanley stays at equalweight and lifts target to 1,250p from1,150p. Anglo American: Morgan Stanley reiterates underweight and lowers target to 850p from 920p. Antofagasta: Morgan Stanley still
Read more